triple-negative breast cancer
GPTKB entity
Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:breast_cancer_subtype
|
| gptkbp:associatedWith |
gptkb:BRCA1_mutation
|
| gptkbp:characterizedBy |
aggressive clinical behavior
high grade tumors |
| gptkbp:has_higher_prevalence_in |
patients with BRCA1 mutations
|
| gptkbp:has_higher_risk_of |
recurrence
|
| gptkbp:has_poor_prognosis_compared_to |
other breast cancer subtypes
|
| gptkbp:is_a_focus_of |
ongoing clinical research
|
| gptkbp:is_diagnosed_by |
immunohistochemistry
|
| gptkbp:is_more_common_in |
African American women
younger women |
| gptkbp:is_not_treated_with |
hormone therapy
HER2-targeted therapy |
| gptkbp:is_treated_with |
chemotherapy
|
| gptkbp:lacks_expression_of |
gptkb:HER2_protein
estrogen receptor progesterone receptor |
| gptkbp:treatment |
gptkb:immunotherapy
PARP inhibitors |
| gptkbp:type |
gptkb:invasive_ductal_carcinoma
|
| gptkbp:bfsParent |
gptkb:Atezolizumab
gptkb:Keytruda gptkb:Tecentriq gptkb:Pembrolizumab gptkb:Trodelvy |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
triple-negative breast cancer
|